A biotech subsidiary has entered into a research collaboration agreement to develop BMP and stem cell loaded 3D printing devices for applications in orthopedics. The subsidiary is Stelis Bioparma (formerly called Agila Biotech) and its partner is Bio-Scaffold International Pte Ltd (BSI), a Singapore-based start-up company. Stelis Bioparm is owned by Strides Arcolab.
Biotech Research Surges in Asia
1 min read Premium comments
Secondary
BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds. Stelis is a biotechnology company whose research efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions. The scientists anticipate working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopaedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion.
The research will be jointly directed by Anand Iyer, CEO, Stelis Biopharma and Margam Chandrasekaran, CEO and chief scientist, Bio-Scaffold. Each company will bear the cost of its contribution to the joint research collaboration.
Stelis Biopharma is building a state-of-the-art facility in Bangalore, India, to research and develop biotherapeutic drugs and devices including biosimilars, biobetters, NBEs, novel formulations and drug loaded devices. The company is also building a fully integrated manufacturing facility at Bio-Xcell’s biotechnology park in Nusajaya, within the Iskandar region of Johor, Malaysia, for the manufacture of biotherapeutics and devices.
Iyer and Chandrasekaran said that their joint collaboration would help harness the synergies of the two companies in advancing the development of novel 3D printed devices for effectively treating various conditions in the orthopedic, and plastic reconstructive arena.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.